TORONTO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced that the Company will participate in the following three events during September and October, 2025: September 8-9 – The H.C. Wainwright 27th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York CitySeptember 16-17 – The iAccess Alpha Virtual Best Ideas Fall Investment ConferenceOctober 9 – The 2025 Cantech Letter Investment Confe ...

In a stock market obsessed with AI, Amazon is losing ground https://t.co/ke9BaHP9OJ ...

🚀 Week in AI: Agents Outperform as Sector SlipsBTC cools; dominance <60%; Altseason Index hits 44! Agents pop as WIRE goes ~6,250% on volume! @NEARProtocol pushes user-owned AI! @AlmanakAI raises $8.45M; @TheUpsiderAI cracks Top-10!Let’s unpack what went down this week in AI. 🧵1/6 ...

This Startup Built A Hospital In India To Test Its AI Software https://t.co/fHW7APW4ff https://t.co/oHz2IG99Ne ...

♪ DANI: IT’S 5:00 A. M. IN NEW YORK CITY.GOOD MORNING, I’M DANI BURGER WITH YOUR "BLOOMBERG BRIEF." MORE TALKS. PRESIDENT TRUMP CALLS FOR A MEETING BETWEEN PRESIDENT PUTIN AND ZELENSKIY AND A TRILATERAL WITH HIMSELF. THE BIG INTEL BET.THE TRUMP ADMINISTRATION WEIGHS A 10% STAKE. SOFTBANK BUYS A SURPRISE $2 BILLION WORTH OF SHARES. PLAYING FOR TIME, STOCKS GO NOWHERE FAST AHEAD OF ALL TIME HIGHS AND RETAIL EARNINGS AND JACKSON HOLE.WE’RE STILL GOING NOWHERE THIS MORNING. THE S&P ENTERED DOWN 0.01%. WE’RE SO ...

The AI Hiring Bonanza Is Making Startups Rethink Equity Payouts https://t.co/UmLz2HRwvH ...

Core Viewpoint - Hemostemix Inc. is positioning itself as the world's first AI-driven autologous stem cell therapy company, focusing on enhancing patient care and operational efficiency through artificial intelligence [2][3]. Patient Care Innovations - The company is implementing HIPAA-compliant precision medicine diagnostics that unify various patient data into a single AI-powered analysis, improving the understanding of patient health journeys [4]. - Acurist.AI is being utilized for early cognitive decline screening, allowing for baseline assessments to monitor memory changes before and after treatment with VesCell™ (ACP-01) [5]. - AI-powered patient engagement tools, including personalized chatbot support, are enhancing patient access and satisfaction during treatment and recovery [5]. - AI-driven insights are assisting healthcare providers in tailoring post-therapy plans to help patients maintain healthier habits [6]. Clinical & Scientific Advancement - AI tools are being used to accelerate research by analyzing patient data to predict treatment responses and refine trial designs for VesCell™ (ACP-01) [7]. - Predictive analytics will model therapy success rates based on co-morbidities, lifestyle patterns, and epigenetic markers [7]. - Intelligent agents are streamlining patient recruitment for clinical trials by rapidly screening profiles against trial criteria [8]. Operational Efficiency - Automated administrative workflows, integrated with HubSpot, are reducing overhead costs by up to 20% through efficient management of scheduling, billing, and follow-ups [9]. - AI is optimizing resource allocation by dynamically adjusting staffing and supply chains based on therapy demand [9]. - A unified data ecosystem is being established to ensure seamless, HIPAA-compliant access to clinical trial data and outcome metrics [9]. Compliance & Security - Real-time AI monitoring is being implemented to detect risks and enforce data protection protocols, safeguarding sensitive health information [10]. Company Background - Hemostemix, founded in 2003, specializes in autologous stem cell therapy and has developed the patented VesCell™ (ACP-01) therapy, which has shown promising results in clinical studies for various cardiovascular conditions [12]. - The company has completed seven clinical studies involving 318 subjects, with significant findings published in peer-reviewed journals, including a reported 0% mortality rate in a specific patient population over a follow-up period of up to 4.5 years [12].

RT BSCN (@BSCNews)🚨 @INJECTIVE BRINGS AI INTO DEFINvidia’s most in-demand chip, the H100, is now onchain. Compute costs = a new market to trade 👇https://t.co/BsCiOEtAxG ...

“Extinction-level” risk is possible given how fast AI is being developed, according to a 2024 U.S. Department of State-commissioned report. (Illustration by Fernando Capeto and Samantha Lee via Google Gemini AI) https://t.co/AoaZcZdwc1 https://t.co/D5bBVOO8le ...

最近高频在玩各种AI产品，感觉它们宣发的预制菜味特别重先拿出yc + product hunt + 邀请码三件套，然后标准镜头怼创始人脸视频：“Hi guys, I am XXX, co-founder of YYY. In the past 3 months we made the first xxx agent in the world…”想想crypto项目也是三件套式宣发，创投体验服了属于是 https://t.co/W4Ed5QN3rN ...